MedTrace Logo

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

NCT07141329 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-10-10

No results posted yet for this study

Summary

This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.

Conditions

Interventions

DRUG

SPN-817

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

Sponsors & Collaborators

  • Supernus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Maciej Gasior, MD, PhD · Supernus Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-30
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07141329 on ClinicalTrials.gov